Summit Therapeutics (SMMT) Non-Current Assets (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Non-Current Assets came in at $31.6 million in Q2 2026, up 113.6% YoY from $14.8 million in Q2 2025, and up 1.12% on a QoQ basis from $31.3 million in Q1 2026.
Summit Therapeutics (SMMT) Non-Current Assets (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Non-Current Assets data on file, last reported at $31.6 million in Q2 2026.
- Quarterly Non-Current Assets rose 113.6% year-over-year to $31.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $109.0 million (up 108.67% YoY) and the FY2025 annual result came in at $30.9 million, up 161.48% from the prior year.
- Non-Current Assets rose to $31.6 million in Q2 2026, from $31.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $31.6 million in Q2 2026 to a low of $6.9 million in Q1 2023.
- A 5-year average of $16.1 million and a median of $13.5 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 59.68% — and 2025, when it soared 161.48%.
- Tracing SMMT's Non-Current Assets over 5 years: stood at $7.5 million in 2022, then soared by 77.53% to $13.2 million in 2023, then slipped by 10.78% to $11.8 million in 2024, then surged by 161.48% to $30.9 million in 2025, then increased by 2.35% to $31.6 million in 2026.
- The last three Non-Current Assets figures came in at $31.6 million (Q2 2026), $31.3 million (Q1 2026), and $30.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 31.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31.61 Mn |
| Mar 31, 2026 | 31.26 Mn |
| Dec 31, 2025 | 30.88 Mn |
| Sep 30, 2025 | 15.26 Mn |
| Jun 30, 2025 | 14.80 Mn |
| Mar 31, 2025 | 13.07 Mn |
| Dec 31, 2024 | 11.81 Mn |
| Sep 30, 2024 | 12.56 Mn |
| Jun 30, 2024 | 13.06 Mn |
| Mar 31, 2024 | 13.52 Mn |
| Dec 31, 2023 | 13.24 Mn |
| Sep 30, 2023 | 13.53 Mn |
| Jun 30, 2023 | 9.87 Mn |
| Mar 31, 2023 | 6.87 Mn |
| Dec 31, 2022 | 7.46 Mn |
| Sep 30, 2022 | 18.21 Mn |
| Jun 30, 2022 | 16.32 Mn |
| Mar 31, 2022 | 17.04 Mn |
| Dec 31, 2021 | 16.06 Mn |
| Sep 30, 2021 | 26.46 Mn |